Results 91 to 100 of about 552 (131)

Novel and potential future therapeutic options in systemic autoimmune diseases. [PDF]

Front Immunol
Balogh L, Oláh K, Sánta S, Majerhoffer N, Németh T.   +4 more
europepmc   +1 more source

The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases. [PDF]

Exp Hematol Oncol
Wang MJ, Zhang HL, Chen F, Guo XJ, Liu QG, Hou J.   +5 more
europepmc   +1 more source

Identification of potential hub genes and drugs in septic kidney injury: a bioinformatic analysis with preliminary experimental validation. [PDF]

Front Med (Lausanne)
Sun S, Ding Y, Yang D, Shen J, Zhang T, Song G, Chen X, Lin Y, Chen R.   +8 more
europepmc   +1 more source

Inflammatory mechanisms in diabetic retinopathy: pathogenic roles and therapeutic perspectives. [PDF]

Am J Transl Res
Qian HY, Wei XH, Huang JO.
europepmc   +1 more source

What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? [PDF]

Ther Adv Musculoskelet Dis
Taylor PC, Feist E, Pope JE, Nash P, Sibilia J, Caporali R, Balsa A.   +6 more
europepmc   +1 more source

Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review). [PDF]

Mol Med Rep
Zhao L, Feng C, Gao YJ, He T.
europepmc   +1 more source

Targeting rheumatoid arthritis: a molecular perspective on biologic therapies and clinical progress. [PDF]

J Biol Eng
Jain A, Bishnoi M, Prajapati SK, Acharya S, Kapre S, Singhvi G, Palakurthi S.   +6 more
europepmc   +1 more source

Incidence and risk factors of tocilizumab-induced hypofibrinogenemia in patients with thyroid eye disease: a single-center retrospective study. [PDF]

Front Endocrinol (Lausanne)
Wang E, Hu Q, Xu S, Zhou J, Wang J, Song Z, Wang X.   +6 more
europepmc   +1 more source